Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Turner, Nicholas C.
12035  Ergebnisse:
Personensuche X
?
1

Optimal targeting of PI3K-AKT and mTOR in advanced oestroge..:

Browne, Iseult M ; André, Fabrice ; Chandarlapaty, Sarat..
The Lancet Oncology.  25 (2024)  4 - p. e139-e151 , 2024
Link: https://doi.org/10.1016/..
 
?
2

Genomic analysis of advanced breast cancer tumors from tala..:

Turner, Nicholas C. ; Laird, A. Douglas ; Telli, Melinda L....
npj Breast Cancer.  9 (2023)  1 - p. , 2023
Link: https://doi.org/10.1038/..
 
?
3

Baseline Mutations and ctDNA Dynamics as Prognostic and Pre..:

Pascual, Javier ; Gil-Gil, Miguel ; Proszek, Paula...
Clinical Cancer Research.  29 (2023)  20 - p. 4166-4177 , 2023
Link: https://doi.org/10.1158/..
 
?
4

Phase Ia/b Study of Giredestrant ± Palbociclib and ± Lutein..:

Jhaveri, Komal L. ; Bellet, Meritxell ; Turner, Nicholas C....
Clinical Cancer Research.  30 (2023)  4 - p. 754-766 , 2023
Link: https://doi.org/10.1158/..
 
?
5

The CDK4/6 inhibitor revolution — a game-changing era for b..:

Morrison, Laura ; Loibl, Sibylle ; Turner, Nicholas C.
Nature Reviews Clinical Oncology.  21 (2023)  2 - p. 89-105 , 2023
Link: https://doi.org/10.1038/..
 
?
6

Genomic profiling and pre-clinical modelling of breast canc..:

Fitzpatrick, Amanda ; Iravani, Marjan ; Mills, Adam...
Nature Communications.  14 (2023)  1 - p. , 2023
Link: https://doi.org/10.1038/..
 
?
7

First-Line Ipatasertib, Atezolizumab, and Taxane Triplet fo..:

Schmid, Peter ; Turner, Nicholas C. ; Barrios, Carlos H....
Clinical Cancer Research.  30 (2023)  4 - p. 767-778 , 2023
Link: https://doi.org/10.1158/..
 
?
8

ESR1 F404 Mutations and Acquired Resistance to Fulvestrant ..:

Kingston, Belinda ; Pearson, Alex ; Herrera-Abreu, Maria Teresa...
Cancer Discovery.  14 (2023)  2 - p. 274-289 , 2023
Link: https://doi.org/10.1158/..
 
?
9

Comparison of Circulating Tumor DNA Assays for Molecular Re..:

Coakley, Maria ; Villacampa, Guillermo ; Sritharan, Prithika...
Clinical Cancer Research.  30 (2023)  4 - p. 895-903 , 2023
Link: https://doi.org/10.1158/..
 
?
10

Author Correction: High p16 expression and heterozygous RB1..:

Palafox, Marta ; Monserrat, Laia ; Bellet, Meritxell...
Nature Communications.  13 (2022)  1 - p. , 2022
Link: https://doi.org/10.1038/..
 
?
11

Neratinib in advanced HER2-positive breast cancer: experien..:

Cunningham, Niamh ; Shepherd, Scott ; Mohammed, Kabir...
Breast Cancer Research and Treatment.  195 (2022)  3 - p. 333-340 , 2022
Link: https://doi.org/10.1007/..
 
?
12

Clinical outcomes in patients with triple negative or HER2 ..:

Okines, Alicia ; Irfan, Tazia ; Asare, Bernice...
Breast Cancer Research and Treatment.  192 (2022)  3 - p. 563-571 , 2022
Link: https://doi.org/10.1007/..
 
?
13

Operational complexity versus design efficiency: challenges..:

Snowdon, Claire ; Kernaghan, Sarah ; Moretti, Laura...
Trials.  23 (2022)  1 - p. , 2022
Link: https://doi.org/10.1186/..
 
?
14

Assessing CSF ctDNA to Improve Diagnostic Accuracy and Ther..:

Fitzpatrick, Amanda ; Iravani, Marjan ; Mills, Adam...
Clinical Cancer Research.  28 (2022)  6 - p. 1180-1191 , 2022
Link: https://doi.org/10.1158/..
 
?
15

Overall Survival with Palbociclib and Fulvestrant in Women ..:

Cristofanilli, Massimo ; Rugo, Hope S. ; Im, Seock-Ah...
Clinical Cancer Research.  28 (2022)  16 - p. 3433-3442 , 2022
Link: https://doi.org/10.1158/..
 
1-15